Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

Peter Rasmussen; Yu-Sok Kim; Rikke Krogh-Madsen; Carsten Lundby; Niels V Olsen; Niels H Secher; Johannes J van Lieshout

doi:10.1096/fj.11-193508

Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

Peter Rasmussen, Yu-Sok Kim, Rikke Krogh-Madsen, Carsten Lundby, Niels V Olsen, Niels H Secher, Johannes J van Lieshout

19 Citations (Scopus)

Abstract

Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n=8) and chronic (5000 IU/week for 13 wk; n=8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 ± 3.7 to 47.6 ± 4.1% (P

Original language	English
Journal	F A S E B Journal
Volume	26
Issue number	3
Pages (from-to)	1343-8
Number of pages	6
ISSN	0892-6638
DOIs	https://doi.org/10.1096/fj.11-193508
Publication status	Published - 2012

Keywords

Adult
Blood Flow Velocity
Blood Pressure
Cerebrovascular Circulation
Cross-Over Studies
Double-Blind Method
Erythropoietin
Exercise
Hematocrit
Homeostasis
Humans
Injections, Intravenous
Injections, Subcutaneous
Male
Oxygen
Oxygen Consumption
Time Factors
Vasoconstriction
Young Adult

Access to Document

10.1096/fj.11-193508

Cite this

@article{7e89f6ce37e94148b90f80139bd25fe4,

title = "Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans",

abstract = "Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n=8) and chronic (5000 IU/week for 13 wk; n=8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 ± 3.7 to 47.6 ± 4.1% (P",

keywords = "Adult, Blood Flow Velocity, Blood Pressure, Cerebrovascular Circulation, Cross-Over Studies, Double-Blind Method, Erythropoietin, Exercise, Hematocrit, Homeostasis, Humans, Injections, Intravenous, Injections, Subcutaneous, Male, Oxygen, Oxygen Consumption, Time Factors, Vasoconstriction, Young Adult",

author = "Peter Rasmussen and Yu-Sok Kim and Rikke Krogh-Madsen and Carsten Lundby and Olsen, {Niels V} and Secher, {Niels H} and {van Lieshout}, {Johannes J}",

year = "2012",

doi = "10.1096/fj.11-193508",

language = "English",

volume = "26",

pages = "1343--8",

journal = "F A S E B Journal",

issn = "0892-6638",

publisher = "Federation of American Societies for Experimental Biology",

number = "3",

}

TY - JOUR

T1 - Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

AU - Rasmussen, Peter

AU - Kim, Yu-Sok

AU - Krogh-Madsen, Rikke

AU - Lundby, Carsten

AU - Olsen, Niels V

AU - Secher, Niels H

AU - van Lieshout, Johannes J

PY - 2012

Y1 - 2012

N2 - Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n=8) and chronic (5000 IU/week for 13 wk; n=8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 ± 3.7 to 47.6 ± 4.1% (P

AB - Administration of erythropoietin (EPO) has been linked to cerebrovascular events. EPO reduces vascular conductance, possibly because of the increase in hematocrit. Whether EPO in itself affects the vasculature remains unknown; here it was evaluated in healthy males by determining systemic and cerebrovascular variables following acute (30,000 IU/d for 3 d; n=8) and chronic (5000 IU/week for 13 wk; n=8) administration of EPO, while the responsiveness of the vasculature was challenged during cycling exercise, with and without hypoxia. Prolonged administration of EPO increased hematocrit from 42.5 ± 3.7 to 47.6 ± 4.1% (P

KW - Adult

KW - Blood Flow Velocity

KW - Blood Pressure

KW - Cerebrovascular Circulation

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Erythropoietin

KW - Exercise

KW - Hematocrit

KW - Homeostasis

KW - Humans

KW - Injections, Intravenous

KW - Injections, Subcutaneous

KW - Male

KW - Oxygen

KW - Oxygen Consumption

KW - Time Factors

KW - Vasoconstriction

KW - Young Adult

U2 - 10.1096/fj.11-193508

DO - 10.1096/fj.11-193508

M3 - Journal article

C2 - 22159148

SN - 0892-6638

VL - 26

SP - 1343

EP - 1348

JO - F A S E B Journal

JF - F A S E B Journal

IS - 3

ER -

Both acute and prolonged administration of EPO reduce cerebral and systemic vascular conductance in humans

Abstract

Keywords

Access to Document

Fingerprint

Cite this